Zai Lab Limited (ZLAB) fair value analysis
Nasdaq · Updated 2026-10-19
ZLAB price how computed
Valuation status
No fair-value estimate yetZLAB has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for ZLAB yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $23.19
- Sector
- Healthcare
- 12-month range
- $16.30–$28.02
- Market cap
- $2.6B
- From 52-week high
- -17.2%
- Shares outstanding
- 112M
- Rank in Healthcare by quality score
- #125 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Zai Lab Limited is a biopharmaceutical company that discovers, develops, and commercializes medicines for oncology, autoimmune disorders, and infectious diseases. The company operates in China and other Asia-Pacific markets, with a research and development presence in the United States.
ZLAB currently ranks #125 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $2.6B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $450M
- Net margin
- -41.9%
- EPS (TTM)
- $-1.71
- Gross margin
- 54.7%
- Debt / equity
- 0.42
- Revenue growth (3-yr avg)
- 17.9%
- Shares outstanding
- 112M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 38 · neutral
- 50-day average
- $25.33
- 200-day average
- $20.73
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 3 beat, 4 missed
- Quarter by quarter
- 2026-06 ▲ beat (+30.3%)
2026-03 ▼ miss (-58.1%)
2025-12 ▼ miss (-4.5%)
2025-09 ▼ miss (-13.8%)
2025-06 ▬ met (0.0%)
2025-03 ▲ beat (+18.2%)
2024-12 ▼ miss (-26.3%)
2024-09 ▲ beat (+46.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 11 buy · 1 hold · 0 sell (12 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $33.1
- Target vs last price
- +42.7%
What our data shows for ZLAB
- Shares are trading in the middle of their 12-month price range of $16.30–$28.02.
- The 14-day relative strength index sits at a neutral 38.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ZLAB's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ZLAB conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — ZLAB's 50/200-day trend state shifted from uptrend to mixed this week, indicating a change in the company's intermediate momentum relative to its longer-term trajectory. The stock remains in the Healthcare sector with a valuation verdict of awaiting full valuation according to TickrTrends' derived indicators.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ZLAB stock undervalued?
TickrTrends has no fair-value estimate for ZLAB yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is ZLAB's TickrTrends verdict?
ZLAB is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does ZLAB compare to other Healthcare stocks?
ZLAB ranks #125 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ZLAB overbought or oversold?
ZLAB's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ZLAB report earnings next?
ZLAB's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does ZLAB usually beat earnings estimates?
Over its last 8 reported quarters ZLAB beat the consensus estimate 3 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ZLAB?
Of 12 analysts covering ZLAB, 11 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $33.1 (+42.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.